Cascade of care among people with hepatitis B in New South Wales, Australia
Journal of Viral Hepatitis · 2023-12 · 30 (12) · 926-938
DOI: 10.1111/jvh.13881 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 08.08.2023. Verfasst von Syed Hassan Bin Usman Shah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Viral Hepatitis Clinical Research Program (VHCRP), The Kirby Institute, UNSW, Sydney, Australia. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Coinfection, Hepatitis B. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health and Aged Care, Australian Government, National Health and Medical Research Council, New South Wales Ministry of Health.
Abstract (Originalsprache)
Hepatitis B virus (HBV) care cascade characterisation is important for monitoring HBV elimination progress. This study evaluated care cascade and factors associated with HBV DNA testing and treatment in New South Wales, Australia. HBV care cascade were determined through linkage of HBV notifications (1993–2017) to Medicare and pharmaceutical benefits schemes (2010–2018). Timely HBV DNA testing was within 4 weeks of HBV notification. Multivariate Cox proportional hazards regression evaluated factors associated with HBV DNA testing and treatment. Among 15,202 people with HBV notification, 10,479 (69%) were tested for HBV DNA. A total of 3179 (21%) initiated HBV treatment. HBV DNA testing was more likely among age ≥45 years (adjusted hazard ratio [aHR] 1.07, 95% CI: 1.02, 1.12), hepatocellular carcinoma (HCC) (aHR 1.23, 95% CI: 1.01, 1.50), coinfection (aHR 1.61, 95% CI: 1.23, 2.09), later notification (2014–2017) (aHR 1.21, 95% CI: 1.16, 1.26) and less likely among females (aHR 0.95, 95% CI: 0.91, 0.99), history of alcohol use disorder (AUD) (aHR 0.77, 95% CI: 0.66, 0.89), HCV coinfection (aHR .62, 95% CI: 0.55, 0.70) and Indigenous peoples (aHR 0.84, 95% CI: 0.71, 0.98). HBV treatment was associated with age ≥45 years (aHR 1.35, 95% CI: 1.24, 1.48), decompensated cirrhosis (aHR 2.07, 95% CI: 1.62, 2.65), HCC (aHR 2.96, 95% CI: 2.35, 3.74), HIV coinfection (aHR 4.27, 95% CI: 3.43, 5.31) and later notification (2014–2017) (aHR 1.37, 95% CI: 1.26, 1.47). HBV treatment was less likely among females (aHR 0.68, 95% CI: 0.63, 0.73) and Indigenous peoples (aHR 0.58, 95% CI: 0.42, 0.80). HBV DNA testing and treatment coverage have increased, but remain sub‐optimal among some key populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Viral Hepatitis Clinical Research Program (VHCRP), The Kirby Institute, UNSW, Sydney, Australia.
ORCID-Profile: Syed Hassan Bin Usman Shah, Behzad Hajarizadeh
Förderung
- Department of Health and Aged Care, Australian Government
- National Health and Medical Research Council
- New South Wales Ministry of Health
- NSW Health
Zitieren
APA
Shah, S. H. B. U., Valerio, H., Hajarizadeh, B., Matthews, G., Alavi, M., & Dore, G. J. (2023). Cascade of care among people with hepatitis B in New South Wales, Australia. Journal of Viral Hepatitis, 30(12), 926-938. https://doi.org/10.1111/jvh.13881
Vancouver
Shah SHBU, Valerio H, Hajarizadeh B, Matthews G, Alavi M, Dore GJ. Cascade of care among people with hepatitis B in New South Wales, Australia. Journal of Viral Hepatitis. 2023;30(12):926-938. doi:10.1111/jvh.13881
BibTeX
@article{Shah2023,
author = {Shah, Syed Hassan Bin Usman and Valerio, Heather and Hajarizadeh, Behzad and Matthews, Gail and Alavi, Maryam and Dore, Gregory J},
title = {Cascade of care among people with hepatitis B in New South Wales, Australia},
journal = {Journal of Viral Hepatitis},
year = {2023},
volume = {30},
number = {12},
pages = {926--938},
doi = {10.1111/jvh.13881}
}
EUVIMED